QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NYSE:ABBV

AbbVie News Headlines

$110.50
-0.36 (-0.32 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$109.21
Now: $110.50
$111.23
50-Day Range
$102.80
MA: $107.04
$112.62
52-Week Range
$62.55
Now: $110.50
$113.41
Volume6.72 million shs
Average Volume7.49 million shs
Market Capitalization$195.08 billion
P/E Ratio23.36
Dividend Yield4.69%
Beta0.84

Headlines

AbbVie (NYSE ABBV) News Headlines Today

Source:
SourceHeadline
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 25 at 8:01 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 24 at 8:03 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 23 at 8:04 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 22 at 8:06 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 21 at 8:01 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 20 at 8:01 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 19 at 8:04 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 18 at 8:25 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:56 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:55 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 17 at 5:54 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 16 at 5:26 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 15 at 5:15 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 14 at 5:01 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 13 at 5:17 PM
How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ UpsideHow to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside
marketbeat.com - January 12 at 5:11 PM
AbbVie (NYSE:ABBV) Upgraded to Sell at BidaskClubAbbVie (NYSE:ABBV) Upgraded to Sell at BidaskClub
marketbeat.com - January 1 at 3:07 AM
Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)
marketbeat.com - December 29 at 8:39 AM
AbbVie (NYSE:ABBV) Downgraded to Strong Sell at BidaskClubAbbVie (NYSE:ABBV) Downgraded to Strong Sell at BidaskClub
marketbeat.com - December 19 at 12:04 AM
AbbVie (NYSE:ABBV) Price Target Raised to $120.00 at Morgan StanleyAbbVie (NYSE:ABBV) Price Target Raised to $120.00 at Morgan Stanley
marketbeat.com - November 30 at 8:37 AM
Doing underway in Alector, AbbVies study of AL002 in Alzheimer’s disease - Seeking AlphaDoing underway in Alector, AbbVie's study of AL002 in Alzheimer’s disease - Seeking Alpha
seekingalpha.com - January 25 at 1:25 PM
European Commission Approves AbbVies RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - PRNewswireEuropean Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - PRNewswire
prnewswire.com - January 25 at 1:25 PM
European Commission Approves AbbVies RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing SpondylitisEuropean Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
finance.yahoo.com - January 25 at 1:24 PM
Breast Cancer Drugs Market : Segments Worth Observing Aiding Growth Factors | Hoffmann-La Roche Ltd., AbbVie IncBreast Cancer Drugs Market : Segments Worth Observing Aiding Growth Factors | Hoffmann-La Roche Ltd., AbbVie Inc
marketwatch.com - January 25 at 3:24 AM
AbbVie Is Raising Several Green Flags - Seeking AlphaAbbVie Is Raising Several Green Flags - Seeking Alpha
seekingalpha.com - January 22 at 12:18 PM
$13.74 Billion in Sales Expected for AbbVie Inc. (NYSE:ABBV) This Quarter$13.74 Billion in Sales Expected for AbbVie Inc. (NYSE:ABBV) This Quarter
americanbankingnews.com - January 21 at 1:22 PM
AbbVie Stock Is Trading Near A 3-Year High — Is It Time To Add ABBV Stock?AbbVie Stock Is Trading Near A 3-Year High — Is It Time To Add ABBV Stock?
finance.yahoo.com - January 19 at 3:57 PM
AbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield - Seeking AlphaAbbVie: Undervalued Dividend Aristocrat Offering A 4.77% Yield - Seeking Alpha
seekingalpha.com - January 18 at 11:22 AM
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - Yahoo FinanceAllergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - Yahoo Finance
finance.yahoo.com - January 16 at 10:21 AM
AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Buy" from BrokeragesAbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - January 16 at 10:17 AM
Zacks: Analysts Anticipate AbbVie Inc. (NYSE:ABBV) Will Post Earnings of $2.86 Per ShareZacks: Analysts Anticipate AbbVie Inc. (NYSE:ABBV) Will Post Earnings of $2.86 Per Share
americanbankingnews.com - January 16 at 8:34 AM
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - PRNewswireAllergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference - PRNewswire
prnewswire.com - January 15 at 1:00 PM
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual ConferenceAllergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
finance.yahoo.com - January 15 at 1:00 PM
3 Green Flags for AbbVie in 2021 and 1 Red Flag - Motley Fool3 Green Flags for AbbVie in 2021 and 1 Red Flag - Motley Fool
fool.com - January 15 at 7:04 AM
Traders Buy High Volume of AbbVie Call Options (NYSE:ABBV)Traders Buy High Volume of AbbVie Call Options (NYSE:ABBV)
americanbankingnews.com - January 13 at 8:56 PM
Genmab receives $40M milestone payment in AbbVie collaboration - Seeking AlphaGenmab receives $40M milestone payment in AbbVie collaboration - Seeking Alpha
seekingalpha.com - January 13 at 3:53 PM
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie - GlobeNewswireGenmab Achieves USD 40 Million Milestone in Collaboration with AbbVie - GlobeNewswire
globenewswire.com - January 13 at 3:53 PM
AbbVie (ABBV) Inks Deal to Acquire Medical Device Company - Yahoo FinanceAbbVie (ABBV) Inks Deal to Acquire Medical Device Company - Yahoo Finance
finance.yahoo.com - January 13 at 3:53 PM
AbbVie (ABBV) Inks Deal to Acquire Medical Device CompanyAbbVie (ABBV) Inks Deal to Acquire Medical Device Company
finance.yahoo.com - January 13 at 3:53 PM
Evolus is up 6% after AbbVie-Cypris Medical dealEvolus is up 6% after AbbVie-Cypris Medical deal
seekingalpha.com - January 13 at 11:03 AM
AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) - Seeking AlphaAbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - January 13 at 7:55 AM
AbbVie in-licenses Dragonfly Therapeutics TriNKET drug candidate - Seeking AlphaAbbVie in-licenses Dragonfly Therapeutics' TriNKET drug candidate - Seeking Alpha
seekingalpha.com - January 12 at 10:29 PM
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - Yahoo FinanceAbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - Yahoo Finance
finance.yahoo.com - January 12 at 10:29 PM
AbbVie (ABBV) to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - StreetInsider.comAbbVie (ABBV) to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call - StreetInsider.com
streetinsider.com - January 12 at 11:35 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate - PRNewswireDragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate - PRNewswire
prnewswire.com - January 12 at 11:35 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug CandidateDragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
finance.yahoo.com - January 12 at 11:35 AM
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference CallAbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
finance.yahoo.com - January 12 at 11:35 AM
AbbVie rated buy at Mizuho despite patent cliff for Humira - Seeking AlphaAbbVie rated buy at Mizuho despite patent cliff for Humira - Seeking Alpha
seekingalpha.com - January 11 at 2:07 PM
AbbVie (NYSE:ABBV) Reaches New 12-Month High at $109.21AbbVie (NYSE:ABBV) Reaches New 12-Month High at $109.21
americanbankingnews.com - January 11 at 1:31 PM
AbbVie Looks Attractive Despite Headwinds - Seeking AlphaAbbVie Looks Attractive Despite Headwinds - Seeking Alpha
seekingalpha.com - January 10 at 11:05 PM
Dividend Diligence On AbbVie With Seeking Alpha - Seeking AlphaDividend Diligence On AbbVie With Seeking Alpha - Seeking Alpha
seekingalpha.com - January 10 at 11:05 PM
AbbVie Looks Attractive Despite HeadwindsAbbVie Looks Attractive Despite Headwinds
seekingalpha.com - January 10 at 9:54 PM
AbbVie Inc. (NYSE:ABBV) Pays A US$1.30 Dividend In Just Four Days - Yahoo FinanceAbbVie Inc. (NYSE:ABBV) Pays A US$1.30 Dividend In Just Four Days - Yahoo Finance
finance.yahoo.com - January 9 at 6:43 PM
How Safe Is AbbVies Dividend? - Motley FoolHow Safe Is AbbVie's Dividend? - Motley Fool
fool.com - January 9 at 1:43 PM
AbbVie Inc. (NYSE:ABBV) Will Pay A US$1.30 Dividend In Four DaysAbbVie Inc. (NYSE:ABBV) Will Pay A US$1.30 Dividend In Four Days
nasdaq.com - January 9 at 8:40 AM
How Safe Is AbbVies Dividend?How Safe Is AbbVie's Dividend?
finance.yahoo.com - January 9 at 8:40 AM
AbbVies (ABBV) Skyrizi Succeeds in Crohns Disease Studies - Yahoo FinanceAbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies - Yahoo Finance
finance.yahoo.com - January 9 at 3:39 AM
AbbVie (ABBV) to Present at the 39th Annual J.P. Morgan Healthcare ConferenceAbbVie (ABBV) to Present at the 39th Annual J.P. Morgan Healthcare Conference
marketwatch.com - January 8 at 10:38 PM
Victoria Park Medispa Launches Emsculpt NEO in CanadaVictoria Park Medispa Launches Emsculpt NEO in Canada
finance.yahoo.com - January 8 at 10:38 PM
AbbVies (ABBV) Skyrizi Succeeds in Crohns Disease Studies - NasdaqAbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies - Nasdaq
nasdaq.com - January 8 at 12:34 PM
How Patience Paid Off for Jim Cramer With AbbVie - TheStreetHow Patience Paid Off for Jim Cramer With AbbVie - TheStreet
thestreet.com - January 8 at 12:34 PM
AbbVie : Skyrizi Shows Improvements In Clinical Responses In Two Phase 3 Studies On Crohns Disease - NasdaqAbbVie : Skyrizi Shows Improvements In Clinical Responses In Two Phase 3 Studies On Crohn's Disease - Nasdaq
nasdaq.com - January 7 at 9:32 PM
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohns Disease - PRNewswireRisankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease - PRNewswire
prnewswire.com - January 7 at 10:39 AM
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohns DiseaseRisankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
finance.yahoo.com - January 7 at 10:39 AM
Insights on the Botulinum Toxin Global Market to 2024 - Featuring Abbvie, Ipsen and Revance Therapeutics - Yahoo FinanceInsights on the Botulinum Toxin Global Market to 2024 - Featuring Abbvie, Ipsen and Revance Therapeutics - Yahoo Finance
finance.yahoo.com - January 6 at 2:38 PM
AbbVies (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies - NasdaqAbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies - Nasdaq
nasdaq.com - January 6 at 2:38 PM
Why AbbVie (ABBV) Could Beat Earnings Estimates Again - NasdaqWhy AbbVie (ABBV) Could Beat Earnings Estimates Again - Nasdaq
nasdaq.com - January 6 at 2:38 PM
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo FinanceAbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
finance.yahoo.com - January 6 at 2:38 PM
AbbVies risankizumab shows positive action in patients with psoriatic arthritis - Seeking AlphaAbbVie's risankizumab shows positive action in patients with psoriatic arthritis - Seeking Alpha
seekingalpha.com - January 5 at 8:19 PM
AbbVie (ABBV) Announces Risankizumab Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients - StreetInsider.comAbbVie (ABBV) Announces Risankizumab Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients - StreetInsider.com
streetinsider.com - January 5 at 3:14 PM
This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.